PMID- 23696124
OWN - NLM
STAT- MEDLINE
DCOM- 20140611
LR  - 20220321
IS  - 1862-8354 (Electronic)
IS  - 1862-8346 (Print)
IS  - 1862-8346 (Linking)
VI  - 7
IP  - 7-8
DP  - 2013 Aug
TI  - Mass spectrometric immunoassay and MRM as targeted MS-based quantitative 
      approaches in biomarker development: potential applications to cardiovascular 
      disease and diabetes.
PG  - 528-40
LID - 10.1002/prca.201200028 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is an important risk factor for cardiovascular 
      disease (CVD)--the leading cause of death in the United States. Yet not all 
      subjects with T2DM are at equal risk for CVD complications; the challenge lies in 
      identifying those at greatest risk. Therapies directed toward treating 
      conventional risk factors have failed to significantly reduce this residual risk 
      in T2DM patients. Thus newer targets and markers are needed for the development 
      and testing of novel therapies. Herein we review two complementary MS-based 
      approaches--mass spectrometric immunoassay (MSIA) and MS/MS as MRM--for the 
      analysis of plasma proteins and PTMs of relevance to T2DM and CVD. Together, 
      these complementary approaches allow for high-throughput monitoring of many PTMs 
      and the absolute quantification of proteins near the low picomolar range. In this 
      review article, we discuss the clinical relevance of the high density lipoprotein 
      (HDL) proteome and Apolipoprotein A-I PTMs to T2DM and CVD as well as provide 
      illustrative MSIA and MRM data on HDL proteins from T2DM patients to provide 
      examples of how these MS approaches can be applied to gain new insight regarding 
      cardiovascular risk factors. Also discussed are the reproducibility, 
      interpretation, and limitations of each technique with an emphasis on their 
      capacities to facilitate the translation of new biomarkers into clinical 
      practice.
CI  - (c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Yassine, Hussein
AU  - Yassine H
AD  - Department of Medicine, University of Southern California, Los Angeles, CA, USA.
FAU - Borges, Chad R
AU  - Borges CR
FAU - Schaab, Matthew R
AU  - Schaab MR
FAU - Billheimer, Dean
AU  - Billheimer D
FAU - Stump, Craig
AU  - Stump C
FAU - Reaven, Peter
AU  - Reaven P
FAU - Lau, Serrine S
AU  - Lau SS
FAU - Nelson, Randall
AU  - Nelson R
LA  - eng
GR  - R24 DK083948/DK/NIDDK NIH HHS/United States
GR  - P30 CA023074/CA/NCI NIH HHS/United States
GR  - P30CA023074/CA/NCI NIH HHS/United States
GR  - P30ES06694/ES/NIEHS NIH HHS/United States
GR  - K23 HL107389/HL/NHLBI NIH HHS/United States
GR  - K23HL107389/HL/NHLBI NIH HHS/United States
GR  - P30 ES006694/ES/NIEHS NIH HHS/United States
GR  - R01 CA065662/CA/NCI NIH HHS/United States
GR  - R24DK090958/DK/NIDDK NIH HHS/United States
GR  - R24 DK090958/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130709
PL  - Germany
TA  - Proteomics Clin Appl
JT  - Proteomics. Clinical applications
JID - 101298608
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
SB  - IM
MH  - Amino Acid Sequence
MH  - Biomarkers/metabolism
MH  - Blood Proteins/chemistry/metabolism
MH  - Cardiovascular Diseases/blood/*metabolism
MH  - Diabetes Mellitus/blood/*metabolism
MH  - Humans
MH  - Immunoassay/*methods
MH  - Mass Spectrometry/*methods
MH  - Molecular Sequence Data
PMC - PMC4029342
MID - NIHMS576417
OTO - NOTNLM
OT  - Apolipoprotein A-I
OT  - Cardiovascular disease (CVD)
OT  - Diabetes
OT  - High density lipoprotein (HDL)
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2013/05/23 06:00
MHDA- 2014/06/12 06:00
PMCR- 2014/08/01
CRDT- 2013/05/23 06:00
PHST- 2012/04/25 00:00 [received]
PHST- 2013/02/04 00:00 [revised]
PHST- 2013/03/30 00:00 [accepted]
PHST- 2013/05/23 06:00 [entrez]
PHST- 2013/05/23 06:00 [pubmed]
PHST- 2014/06/12 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - 10.1002/prca.201200028 [doi]
PST - ppublish
SO  - Proteomics Clin Appl. 2013 Aug;7(7-8):528-40. doi: 10.1002/prca.201200028. Epub 
      2013 Jul 9.